ClinicalTrials.gg

Program

izalontamab brengitecan

Also written as “BL-B01D1”, “Iza-bren” and “BMS-986507”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Triple Negative Breast Neoplasms · Breast Neoplasms · Carcinoma, Transitional Cell, led by 2 companies.

Furthest: phase 3, since Oct 25, 202355 company-led studies, 55 open or runningLicense: SystImmune (Biokin) → Bristol Myers Squibb, Dec 2023Next primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical5050 open or runningphase 3since Oct 25, 2023Jan 4, 2022Nov 2026phase 3 · NCT06118333
Bristol-Myers Squibb55 open or runningphase 3since Apr 8, 2025Sep 26, 2024Mar 13, 2028phase 3 · NCT06926868
  • Named in Bristol-Myers Squibb’s own pipeline as iza-bren, phase 3, as of Oct 29, 2026 (source).

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

Not listed one by one: 37 earlier studies, Jan 4, 2022 to May 11, 2025.

  1. Dec 11, 2023Bristol Myers Squibb licensed it from SystImmune (Biokin)LicenseOutside mainland China, developed and sold jointly in the US · announced · SystImmune and Bristol Myers Squibb (release)
  2. May 20, 2025Phase 3 study in Carcinoma, Ovarian EpithelialSichuan Biokin Pharmaceutical · NCT06994195 · 450 planned · China
  3. Jun 20, 2025Phase 2 study in Uterine Cervical NeoplasmsSichuan Biokin Pharmaceutical · NCT07054567 · 96 planned · China
  4. Jul 31, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT07100080 · 661 planned · United States, Argentina, Belgium and more
  5. Aug 5, 2025Phase 3 study in Urinary Bladder NeoplasmsBristol-Myers Squibb · NCT07106762 · 470 planned · United States, Argentina, Australia and more
  6. Mar 25, 2026Phase 3 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT07502300 · 562 planned · China
  7. Apr 21, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaSichuan Biokin Pharmaceutical · NCT07554456 · 90 planned · China
  8. May 6, 2026Phase 3 study in Biliary Tract NeoplasmsSichuan Biokin Pharmaceutical · NCT07582315 · 538 planned · China
  9. Jun 7, 20264 phase 3 studiesSichuan Biokin Pharmaceutical · NCT07640789, NCT07648914, NCT07642024 and 1 more
  10. Jun 26, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT07680790 · 850 planned · United States, Argentina, Australia and more
  11. Jul 20, 20263 phase 3 studiesSichuan Biokin Pharmaceutical · NCT07729956, NCT07739199, NCT07739186
  12. Aug 20, 2026Phase 3 study in Nasopharyngeal CarcinomaSichuan Biokin Pharmaceutical · NCT07783321 · 404 planned · China
  13. Aug 27, 2026Phase 2 study in Nasopharyngeal CarcinomaSichuan Biokin Pharmaceutical · NCT07797881 · 60 planned · China
  14. Sep 14, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungSichuan Biokin Pharmaceutical · NCT07827261 · 36 planned · China
  15. Oct 9, 2026Primary completion moved from 2026-08 to 2027-06Date moved laterphase 2 · +10 months · NCT06498986

Ahead

  1. Nov 2026Primary completion: phase 3 study in Nasopharyngeal CarcinomaSichuan Biokin Pharmaceutical · NCT06118333
  2. Dec 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT06500026
  3. Dec 2026Primary completion: phase 2 study in Triple Negative Breast NeoplasmsSichuan Biokin Pharmaceutical · NCT06471205
  4. Dec 2026Primary completion: phase 2 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT06437509

TargetBeta

“A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a cathepsin-B cleavable linker, to the camptothecin derivative …”NCIt, read by Claude
“A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
CS5007ruleCStone Pharmaceuticalsphase 11

Studies

All 55 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07827261Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingSichuan Biokin PharmaceuticalDec 202836
NCT07797881Nasopharyngeal Carcinoma · China2Not yet recruitingSichuan Biokin PharmaceuticalDec 203060
NCT07783321Nasopharyngeal Carcinoma · China3Not yet recruitingSichuan Biokin PharmaceuticalDec 2033404
NCT07739199Squamous Non-small-cell Lung Cancer · China3RecruitingSichuan Biokin PharmaceuticalDec 2029326
NCT07739186Non-squamous Non-small Cell Lung Cancer · China3RecruitingSichuan Biokin PharmaceuticalDec 2029166
NCT07729956Triple Negative Breast Neoplasms · China3RecruitingSichuan Biokin PharmaceuticalDec 2029436
NCT07680790Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbDec 30, 2031850
NCT07648914Breast Neoplasms · China3RecruitingSichuan Biokin PharmaceuticalDec 2028446
NCT07642024Carcinoma, Non-Small-Cell Lung · China3RecruitingSichuan Biokin PharmaceuticalDec 203290
NCT07641855Castration-resistant Prostate Cancer · China3Not yet recruitingSichuan Biokin PharmaceuticalDec 2028180
NCT07640789Carcinoma, Non-Small-Cell Lung · China3RecruitingSichuan Biokin PharmaceuticalDec 2030418
NCT07582315Biliary Tract Neoplasms · China3RecruitingSichuan Biokin PharmaceuticalDec 2028538
NCT07554456Esophageal Squamous Cell Carcinoma · China3RecruitingSichuan Biokin PharmaceuticalDec 202890
NCT07502300Small Cell Lung Carcinoma · China3RecruitingSichuan Biokin PharmaceuticalDec 2029562
NCT07106762Urinary Bladder Neoplasms · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbJan 26, 2029470
NCT07100080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more3RecruitingBristol-Myers SquibbDec 15, 2028661
NCT07054567Uterine Cervical Neoplasms · China2RecruitingSichuan Biokin PharmaceuticalMay 202796
NCT06994195Carcinoma, Ovarian Epithelial · China3RecruitingSichuan Biokin PharmaceuticalJun 2027450
NCT06986785Advanced Hepatocellular Carcinoma · China2RecruitingSichuan Biokin PharmaceuticalMay 202774
NCT06978114Advanced Biliary Tract Cancer · China2RecruitingSichuan Biokin PharmaceuticalMay 202746
NCT06962787Kidney Neoplasms · China2RecruitingSichuan Biokin PharmaceuticalMay 2027260
NCT06926868Breast Neoplasms · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbMar 13, 2028600
NCT06857175Carcinoma, Transitional Cell · China3Active, not recruitingSichuan Biokin PharmaceuticalJun 2027515
NCT06838273Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingSichuan Biokin PharmaceuticalDec 2028724
NCT06787664Chordoma · China2Active, not recruitingSichuan Biokin PharmaceuticalJun 202727
NCT06618287Lung Neoplasms · United States, Australia, Canada and more2RecruitingBristol-Myers SquibbFeb 26, 2031416
NCT06598787Glioblastoma · China2RecruitingSichuan Biokin PharmaceuticalOct 202620
NCT06500026Small Cell Lung Carcinoma · China3Active, not recruitingSichuan Biokin PharmaceuticalDec 2026722
NCT06498986Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingSichuan Biokin PharmaceuticalJun 202776
NCT06475300Carcinoma, Non-Small-Cell Lung · China2RecruitingSichuan Biokin PharmaceuticalJun 2027570
NCT06471205Triple Negative Breast Neoplasms · China2RecruitingSichuan Biokin PharmaceuticalDec 202652
NCT06437522Squamous Cell Carcinoma of Head and Neck · China2RecruitingSichuan Biokin PharmaceuticalJun 202746
NCT06437509Small Cell Lung Carcinoma · China2RecruitingSichuan Biokin PharmaceuticalDec 202666
NCT06405425Carcinoma, Transitional Cell · China2RecruitingSichuan Biokin PharmaceuticalDec 202652
NCT06382142Triple Negative Breast Neoplasms · China3Active, not recruitingSichuan Biokin PharmaceuticalJan 13, 2026418
NCT06382129Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingSichuan Biokin PharmaceuticalDec 2026698
NCT06382116Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingSichuan Biokin PharmaceuticalAug 2026432
NCT06343948HR+HER2- Breast Cancer · China3Active, not recruitingSichuan Biokin PharmaceuticalAug 2026383
NCT06304974Esophageal Squamous Cell Carcinoma · China3Active, not recruitingSichuan Biokin PharmaceuticalOct 17, 2025497
NCT06118333Nasopharyngeal Carcinoma · China3Active, not recruitingSichuan Biokin PharmaceuticalNov 2026386
NCT06042894Breast Neoplasms · China2RecruitingSichuan Biokin PharmaceuticalDec 202658
NCT06006169Squamous Cell Carcinoma of Head and Neck · China2RecruitingSichuan Biokin PharmaceuticalDec 2026186
NCT06008054Esophageal Neoplasms · China2RecruitingSichuan Biokin PharmaceuticalDec 2026376
NCT05990803Uterine Cervical Neoplasms · China2RecruitingSichuan Biokin PharmaceuticalDec 2026130
NCT05965856Carcinoma, Transitional Cell · China2RecruitingSichuan Biokin PharmaceuticalDec 202652
NCT05956587Carcinoma, Non-Small-Cell Lung · China2RecruitingSichuan Biokin PharmaceuticalDec 2026121
NCT05983432Carcinoma, Non-Small-Cell Lung · United States, France, Italy and more1RecruitingSichuan Biokin PharmaceuticalApr 20, 2030540
NCT05924841Small Cell Lung Carcinoma · China2RecruitingSichuan Biokin PharmaceuticalDec 2026100
NCT05880706Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingSichuan Biokin PharmaceuticalJul 2027198
NCT05803018Ovarian Neoplasms · China2RecruitingSichuan Biokin PharmaceuticalDec 202638
NCT05785039Urologic Neoplasms · China2RecruitingSichuan Biokin PharmaceuticalDec 202676
NCT05470348Breast Neoplasms · China1RecruitingSichuan Biokin PharmaceuticalDec 202636
NCT05262491Digestive System Neoplasms · China1RecruitingSichuan Biokin PharmaceuticalDec 202696
NCT05393427Carcinoma, Renal Cell · China1Active, not recruitingSichuan Biokin PharmaceuticalDec 20254
NCT05194982Neoplasm Metastasis · China1RecruitingSichuan Biokin PharmaceuticalDec 2026570

How it is read

Names in the registry

  • “BL-B01D1”, 49 entries
  • “Iza-bren”, 4 entries
  • “BMS-986507”, 1 entry
  • “BL-B01D1 for Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.